NCT06742021 Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer Status RECRUITING Phase NA
NCT06722885 Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System Status WITHDRAWN Phase N/A
NCT06716580 EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations Status RECRUITING Phase NA
NCT06698042 A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06692972 The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy Status RECRUITING Phase N/A
NCT06691776 Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE) Status RECRUITING Phase NA
NCT06690385 DEPRECAP: Lung Cancer Screening Programme by LDCT for Patients With COPD or Emphysema. Status RECRUITING Phase N/A
NCT06689488 Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates Status RECRUITING Phase N/A
NCT06688656 Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC Status NOT_YET_RECRUITING Phase PHASE2
NCT06688422 Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy Status RECRUITING Phase NA
NCT06685718 A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Status TERMINATED Phase PHASE1
NCT06685458 Constructing a Predictive Model for Differentiating Between Benign and Malignant Solid Pulmonary Nodules Based on Clinical and Imaging Features. Status NOT_YET_RECRUITING Phase N/A
NCT06685133 Prospective Evaluation of the Tool-in-lesion Technology of the Galaxy System in Routine Clinical Practice Status ACTIVE_NOT_RECRUITING Phase N/A
NCT06682793 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression Status RECRUITING Phase PHASE1/PHASE2
NCT06673329 Brodalumab in the Treatment of Immune-Related Adverse Events Status RECRUITING Phase PHASE1
NCT06653478 Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment Status RECRUITING Phase N/A